Novartis Ag Stock Market Value
| NVSEF Stock | USD 101.26 1.64 1.59% |
| Symbol | Novartis |
Novartis 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Novartis' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Novartis.
| 12/31/2024 |
| 01/30/2025 |
If you would invest 0.00 in Novartis on December 31, 2024 and sell it all today you would earn a total of 0.00 from holding Novartis AG or generate 0.0% return on investment in Novartis over 30 days. Novartis is related to or competes with Roche Holding, AstraZeneca PLC, Roche Holding, Sanofi ADR, Bristol-Myers Squibb, Bayer AG, and Astellas Pharma. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide More
Novartis Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Novartis' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Novartis AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 12.02 | |||
| Value At Risk | (4.14) | |||
| Potential Upside | 4.12 |
Novartis Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novartis' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Novartis' standard deviation. In reality, there are many statistical measures that can use Novartis historical prices to predict the future Novartis' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.10) | |||
| Total Risk Alpha | (0.32) | |||
| Treynor Ratio | 0.9882 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novartis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Novartis AG Backtested Returns
Novartis AG has Sharpe Ratio of -0.0112, which conveys that the firm had a -0.0112 % return per unit of risk over the last 3 months. Novartis exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Novartis' Standard Deviation of 2.27, risk adjusted performance of (0.03), and Mean Deviation of 1.42 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.11, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Novartis are expected to decrease at a much lower rate. During the bear market, Novartis is likely to outperform the market. At this point, Novartis AG has a negative expected return of -0.026%. Please make sure to verify Novartis' treynor ratio, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Novartis AG performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.56 |
Modest predictability
Novartis AG has modest predictability. Overlapping area represents the amount of predictability between Novartis time series from 31st of December 2024 to 15th of January 2025 and 15th of January 2025 to 30th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Novartis AG price movement. The serial correlation of 0.56 indicates that roughly 56.0% of current Novartis price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.56 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 2.64 |
Novartis AG lagged returns against current returns
Autocorrelation, which is Novartis pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Novartis' pink sheet expected returns. We can calculate the autocorrelation of Novartis returns to help us make a trade decision. For example, suppose you find that Novartis has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Novartis regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Novartis pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Novartis pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Novartis pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Novartis Lagged Returns
When evaluating Novartis' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Novartis pink sheet have on its future price. Novartis autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Novartis autocorrelation shows the relationship between Novartis pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Novartis AG.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
Other Information on Investing in Novartis Pink Sheet
Novartis financial ratios help investors to determine whether Novartis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.